Clinical Trial Update: Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial [Phase 3]

View source ↗

Summary

Phase 3 randomized trial BEAT HFpEF evaluating inhaled beta-adrenergic agonists for pulmonary vascular disease in heart failure with preserved ejection fraction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Inhaled beta-adrenergic agonist (class)

Snippet

Sponsor: Mayo Clinic | Conditions: Congestive Heart Failure, Heart Failure, Left-Sided | Phase 3 | Status: COMPLETED | Results posted: 2019-02-05